Participant flow

Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy · Source last updated 2014-02-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.

   id

   FG000

   title

   Arm I - Methylphenidate Hydrochloride

2. description

   Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.

   id

   FG001

   title

   Arm II -Modafinil

3. description

   Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.

   id

   FG002

   title

   Arm III Placebo

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice